循环生物标志物和膜间皮瘤的向治疗
Christopher R Grant1, Lyudmila Bazhenova1, Karen M Yun1
1Division of Hematology-Oncology, Moores Cancer Center at UC San Diego Health, San Diego, CA 92093, USA.
Cancers
|December 11, 2025
概括
胸腔间皮瘤 (PM) 研究正在推进,但缺乏诊断生物标志物和向疗法. 本综述涵盖了新兴的生物标志物和这种罕见癌症的潜在药物标.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 排骨间皮瘤 (PM) 是一种罕见的,具有有限治疗选择的侵袭性癌症.
- 目前的标准治疗包括化疗,VEGF抑制和免疫治疗,但缺乏向治疗.
- 对于PM中验证的诊断和预后生物标志物有着至关重要的需求.
研究的目的:
- 审查肺部间皮瘤的新兴诊断和预后生物标志物.
- 讨论PM中可能有针对性的分子变化.
- 检查PM中针对性治疗的正在进行的临床试验.
主要方法:
- 关于PM分子变化的最新研究的文献综述.
- 对诊断和预后生物标志物研究的分析.
- 针对PM的向治疗试验的摘要.
主要成果:
- 新兴的生物标志物显示出PM诊断和预后的前景.
- 颗粒物中的几种分子变化是潜在的治疗点.
- 许多临床试验正在研究PM的向治疗方法.
结论:
- 了解颗粒物分子变化的进展为针对性治疗铺平了道路.
- 生物标志物发现对于改善PM患者的治疗结果至关重要.
- 目前正在进行的试验为PM的新治疗策略提供了希望.
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Pleural Disorders: Types and Brief Description
561
The pleura is a vital part of the respiratory system. It's a double-layered membrane surrounding the lungs and lining the chest cavity. The two layers of the pleura are:
561


